Notizie AIOM – anno XVI n. 662
FDA Approves Abiraterone for High-Risk Prostate Cancer
February 8, 2018 - The FDA has approved abiraterone acetate in combination with prednisone for patients with metastatic high-risk castration-sensitive prostate cancer, based on findings from the phase III LATITUDE trial. The approval, which was announced by the company developing ...Leggi tutto
Women taking Ulipristal acetato for uterine fibroids to have regular liver tests while EMA review is ongoing
February 9, 2018 - European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is currently reviewing the benefits and risks with ulipristal acetato, following reports of serious liver injury, including liver failure leading to transplantation. As ...Leggi tutto
ASCO Clinical Practice Guideline: Treatment of Malignant Pleural Mesothelioma
February 6, 2018 - As reported by Hedy L. Kindler, MD, of the University of Chicago, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on treatment of malignant pleural mesothelioma. The guideline was informed by a systematic ...Leggi tutto
ASCO Examines the Current Oncology Clinical Pathways Landscape
February 7, 2018 - The American Society of Clinical Oncology (ASCO) today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice ...Leggi tutto
Binimetinib/Encorafenib Positive OS Data Released as FDA Weighs Melanoma Approval
February 6, 2018 - Treatment with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib improved survival versus single-agent vemurafenib in patients with BRAF-mutant advanced, unresectable or metastatic melanoma, according to updated findings from the phase III ...Leggi tutto
Management Board started building approval process of EMA premises in Amsterdam
February 7, 2018 - The European Medicines Agency’s (EMA) Management Board met yesterday in an extraordinary session to discuss EMA’s future premises in Amsterdam. EMA will move from London to Amsterdam before the end of March 2019, when the United Kingdom withdraws ...Leggi tutto
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
The KEYNOTE-028 trial ( ClinicalTrials.gov identifier: NCT02054806) was designed to assess the safety and efficacy ofpembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts. Here, we present the results from the cohort of patients with advanced ...Leggi tutto